Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses

详细信息    查看全文

• 作者：Mike D. Shelley ; Malcolm D. Mason ; Howard Kynaston
• 关键词：Superficial bladder cancer ; Intravesical therapy ; Systematic review ; Randomised trials ; Meta-analyses
• 刊名：Cancer Treatment Reviews
• 出版年：2010
• 出版时间：May 2010
• 年：2010
• 卷：36
• 期：3
• 页码：195-205
• 全文大小：209 K

文摘

Summary

Background

In 2002 there were estimated to be 357,000 new cases of bladder cancer worldwide and 145,000 deaths making bladder cancer the 9th most common malignancy globally. At diagnosis, 60–80 % of tumours are superficial and endoscopic resection is the initial treatment for this disease. In patients with low, medium or high risk disease, about 20 % , 40 % and 90 % , respectively, will develop tumour recurrence. To delay or prevent recurrence, intravesical therapy is routinely used. Commonly used intravesical agents include immunotherapy with BCG and chemotherapy with cytotoxics such as Mitomycin C, Adriamycin, Epirubicin and Gemcitabine. However, controversy exists as to which agent and schedule should be used.

Methods

An overarching search of the literature was used to identify relevant studies to assess the clinical benefit of intravesical therapy and provide clinical guidance in a comprehensive systematic review of randomised trials and meta-analyses of intravesical therapy for superficial bladder cancer. Findings and interpretation the search identified over 80 randomised trials and 11 meta-analyses. The extensive evidence suggests that an immediate post-operative instillation of a chemotherapeutic agent, such as Mitomycin C or Epirubicin, is effective in reducing tumour recurrence. In intermediate or high risk patients, further intravesical induction and maintenance therapy with BCG is recommended.

Intravesical chemotherapy with either Mitomycin C or Epirubicin would be an option for those patients failing or who are unsuitable for BCG therapy. Intravesical BCG is superior to chemotherapy in terms of complete response and disease-free survival. However, there is no conclusive evidence that one agent is superior in terms of overall survival.